Pharmacy · Independent exam preparation
BCGP Geriatric Pharmacy: Clinical Decisions and Practice Guide Study Guide
Practise geriatric medication decisions: assess function and cognition, individualize treatment, prevent medication harm, and interpret evidence for BCGP preparation.
By CertMedbry · Updated 30 October 2026
Learn to distinguish delirium from chronic cognitive impairment, recognize medication-related harm, individualize treatment goals, and make defensible monitoring and deprescribing decisions. This selective guide contains 60 concepts, 20 independent practice questions, and 20 flashcards, distributed approximately across the BPS domain weights of 29%, 50%, and 21%. The official examination content outline defines the full scope, including topics beyond these selected lessons.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification level does this guide address?
The Geriatric Pharmacy Specialty Certification Examination awards the Board-Certified Geriatric Pharmacist designation, BCGP, through the Board of Pharmacy Specialties. It is specialty certification for eligible pharmacists who assess, design, implement, monitor, modify, and advise on medication treatment for older adults.
BPS Geriatric Pharmacy · BCGP Examination Specifications — Effective January 2024
How does the historical CGP designation relate to BCGP?
The former Certified Geriatric Pharmacist credential transferred from CCGP to BPS and became BCGP on January 1, 2017. Transitional use of either designation continued until January 1, 2018. This guide addresses the current successor examination, not a separate current CGP examination.
Certified Geriatric Pharmacist Credential Moves to BPS · BPS Update on Specialties
Which blueprint applies, and what are its domain weights?
The January 2024 specifications have an ECO creation date of June 2022. The BPS outline index verified October 11, 2026, labels this document for 2025 administrations onward and anticipates a separate outline for August 2027 onward. Its domains are Geriatric Patient Population, 29%; Therapeutics and Patient Management, 50%; and Professional Practice, 21%. Applicability follows the examination administration date.
BPS Examination Content Outlines · BCGP Examination Specifications — Effective January 2024
How many questions are scored, and how much examination time is provided?
The January 2024 specifications state 150 items: 125 scored and 25 unscored. The current BPS Candidate's Guide identifies the unscored items as pretest items and confirms that the 3-hour-45-minute administration includes the introduction and tutorial. See the [BPS Candidate's Guide](https://bpsweb.org/candidates-guide/).
What delivery method, navigation, and item styles are established?
The current [BPS Candidate's Guide](https://bpsweb.org/candidates-guide/) describes computer-submitted answers, predominantly four-option multiple-choice items, and forward-only navigation: candidates cannot return to a previous item after advancing. Some specialties use additional item styles. These general provisions do not establish BCGP-specific adaptive behavior. This guide uses four-option single-best-answer learning questions and does not claim to reproduce the examination interface.
BPS Geriatric Pharmacy · BCGP Examination Specifications — Effective January 2024
Do different eligibility pathways lead to different examinations?
The specifications describe one BCGP specialty examination with several eligibility routes. In addition to qualifying pharmacy education and active licensure or registration, routes include qualifying practice experience, PGY1 residency plus qualifying experience, or a qualifying PGY2 geriatric pharmacy residency. Education and licensure provisions include jurisdictions outside the United States. These are eligibility routes, not separate examination variants; consult current BPS requirements before applying.
How should this guide be used alongside the full outline?
The 60 concepts use a 17/30/13 domain distribution; questions and flashcards each use 6/10/4. These approximate the official weights while allowing useful clinical examples. The selected lessons teach assessment, medication safety, selected pharmacotherapy, ethics, quality improvement, evidence interpretation, and economics. Pharmacy regulatory requirements, Medicare/HEDIS examples, elder abuse and neglect assessment, and broader disease-specific pharmacotherapy are omitted and require additional study. Other outline areas receive only selected examples. The official outline defines the full scope. Consult current BPS candidate information for application fees and passing-score information.
This guide prepares pharmacists for BPS specialty certification in geriatric pharmacy and the BCGP designation. CGP is the historical predecessor designation. These independently authored learning materials are not official BPS questions or a prediction of examination performance.
Outline used: Verified for 2026-10-11: BCGP Examination Specifications, effective January 2024, ECO created June 2022. BPS currently links this document under '2025 Administration and onward'; a replacement is anticipated for August 2027 onward. The workbook's Certified Geriatric Pharmacist (CGP) label is historical: BPS documents its transition to Board-Certified Geriatric Pharmacist (BCGP) on January 1, 2017. The assigned CGP slug is preserved for the current successor examination.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Geriatric Patient Population29%
1.Why can a low serum creatinine conceal impaired kidney function?
Serum creatinine reflects both creatinine production and kidney elimination. An older adult with reduced muscle mass may produce little creatinine, so a seemingly reassuring concentration can coexist with reduced filtration. Interpret creatinine-based estimates alongside body composition, illness, and the consequences of dosing error. When the estimate is unreliable or close to a treatment threshold, a combined creatinine–cystatin C estimate can improve assessment rather than assuming that a low creatinine proves normal clearance.
Apply it
An older adult has lost substantial muscle mass during prolonged illness, yet serum creatinine remains unchanged. Before approving a renally cleared medicine with a narrow safety margin, question whether creatinine production is masking reduced filtration.
Common pitfall: Treating a laboratory value within its reference range as proof of normal clearance overlooks muscle mass and can support excessive exposure to renally eliminated medicines.
NIDDK: Determining Drug Dosing in Adults with Chronic Kidney Disease
2.Which features distinguish delirium from a stable cognitive baseline?
Delirium develops over a short period and commonly fluctuates, with impaired attention, altered awareness, and changes in thinking. A new inability to follow conversation over hours is more concerning for delirium than a longstanding memory complaint alone. Establish the usual cognitive baseline with someone who knows the patient. New symptoms require evaluation for contributing illness, medication effects, withdrawal, or physiological disturbance, including when chronic dementia is already present.
Apply it
A resident with stable memory impairment suddenly cannot follow simple instructions and alternates between agitation and drowsiness. Compare the change with yesterday's baseline and seek an acute medical and medication assessment.
Common pitfall: Attributing every cognitive change to established dementia delays recognition of an acute syndrome. Chronic impairment and superimposed delirium can occur in the same person.
3.How does hypoactive delirium present?
Hypoactive delirium may appear as unusual quietness, reduced movement, sleepiness, or diminished engagement rather than agitation. The discriminating clue is an acute change in attention or awareness from the person's usual state. A patient who becomes less troublesome can still be deteriorating. Assess onset, fluctuation, medication exposure, hydration, and illness rather than using disruptive behavior as the threshold for concern. Reduced interaction deserves the same attention as new agitation.
Apply it
After hospitalization, a normally talkative patient becomes withdrawn and repeatedly drifts off during medication teaching. The family describes a change over one day, making assessment for hypoactive delirium more appropriate than praising improved behavior.
Common pitfall: Equating delirium with agitation misses quiet presentations. Sedation, depression, and hypoactive delirium can look similar, so onset and attention are essential discriminating observations.
4.Why should delirium assessment consider several simultaneous contributors?
Delirium can result from several interacting stresses, including illness, dehydration, medication effects, withdrawal, pain, and environmental disruption. Identifying one possible contributor does not establish that it is the only cause. Review recent starts, stops, and dose changes while assessing physiological and environmental factors. Supportive measures such as orientation, sleep support, familiar contact, and access to hearing or visual aids complement treatment of the underlying contributors rather than replacing that treatment.
Apply it
An older inpatient becomes inattentive after surgery, poor fluid intake, and a new sedating medicine. Review all three changes and the clinical examination instead of attributing the entire presentation to an unfamiliar room alone.
Common pitfall: Selecting one convenient explanation can leave other reversible contributors untreated. Supportive orientation is valuable but does not substitute for evaluating new illness or medication toxicity.
5.What separates instrumental activities from basic daily activities?
Instrumental activities of daily living describe tasks needed for independent community living, such as shopping, transportation, finances, food preparation, and medication management. Basic daily activities concern personal self-care. The Lawton IADL scale helps identify where support is needed and can reveal loss of independence before basic self-care fails. Interpret performance in context: lack of opportunity, customary household roles, sensory limitations, and physical disability can influence whether a person performs a task.
Apply it
A patient dresses and bathes independently but can no longer organize transport or pay bills reliably. Document these instrumental limitations and arrange targeted assistance instead of describing overall daily function as fully independent.
Common pitfall: Independent bathing does not establish independent community functioning. Conversely, never having performed a household task does not by itself demonstrate a new cognitive or functional decline.
HIGN: The Lawton Instrumental Activities of Daily Living Scale · HIGN Lawton IADL Assessment
6.How should medication-management ability be assessed functionally?
Medication-management ability includes obtaining medicines, identifying the correct product, organizing doses, and taking them at the intended times. A patient may describe a regimen accurately yet struggle to execute it because of vision, dexterity, memory, or task complexity. Functional assessment should determine which steps the person can complete and which require assistance. Match support to the observed limitation rather than using a diagnosis or living arrangement as a substitute for assessment.
Apply it
A patient explains each prescription correctly but cannot open the packaging or distinguish similar tablets. Observe the actual task and arrange accessible packaging or assistance, then verify that the revised system works in practice.
Common pitfall: Accurate verbal recall does not prove successful administration. Automatically transferring all responsibility to a caregiver can also remove independence that remains achievable with targeted support.
7.Why do falls warrant a medication contribution assessment?
Falls can reflect interacting problems in balance, attention, blood pressure, and physical function. Medicines that cause sedation, impaired psychomotor performance, or syncope may add to that vulnerability. The AGS Beers Criteria identify medication classes of concern in people with a history of falls or fractures. Examine the timing of falls against medication changes and assess cumulative exposure. A medication review supplements evaluation of other causes; it does not establish that every fall is drug-induced.
Apply it
A patient develops nighttime falls after a sedating medicine is added to an already complex regimen. Review the new exposure and other central nervous system medicines while the team evaluates gait, environment, and physiological contributors.
Common pitfall: Calling a medicine the sole cause without assessment is premature. Dismissing repeated falls as unavoidable aging can also preserve a modifiable medication-related risk.
8.How can aging-related hepatic changes prolong sedative exposure?
Reduced hepatic metabolism in older adults can slow clearance of certain benzodiazepines and prolong exposure. Longer-acting agents with active metabolites may accumulate, so switching to one for tapering can increase toxicity risk. Kidney assessment alone does not capture this mechanism.
Apply it
Before replacing an older adult's benzodiazepine with diazepam, assess hepatic function, accumulation risk, and whether direct tapering is preferable.
Common pitfall: A longer half-life can smooth withdrawal but also prolong sedation. A switch is not automatically safer.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
9.How does increased CNS sensitivity differ from reduced drug clearance?
Increased CNS sensitivity is a pharmacodynamic change: a given exposure can produce greater effects. Reduced clearance is pharmacokinetic: exposure lasts longer or accumulates. Older adults can experience both with benzodiazepines, increasing cognitive and balance-related harm even when a dose appears small.
Apply it
Assess new sedation and unsteadiness after a low benzodiazepine dose rather than dismissing toxicity because the dose is modest.
Common pitfall: Normal kidney function does not establish normal CNS sensitivity. Review clinical effects as well as elimination.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
10.What makes cumulative anticholinergic exposure clinically important?
Anticholinergic effects can impair cognition and contribute to dry mouth, constipation, urinary retention, and other adverse outcomes. Several medicines with anticholinergic properties may create a clinically important burden even when no single medicine appears dominant. The Beers Criteria emphasize considering total anticholinergic exposure during medication review. Look across prescription and nonprescription products, link symptoms to timing, and consider alternatives that address the indication with less burden when feasible.
Apply it
An older adult taking a bladder medicine adds an over-the-counter sleep aid and develops constipation and confusion. Review both products for anticholinergic effects before treating the new symptoms as unrelated disorders.
Common pitfall: Reviewing only prescriptions can miss a major contributor. Replacing one anticholinergic product with another may preserve the same mechanism and fail to reduce total burden.
11.How should decision-making capacity be approached?
Informed decisions require an ability to understand relevant information and treatment alternatives and appreciate their implications for one's circumstances. Assess the patient's participation in the particular decision rather than inferring incapacity from age or diagnosis. Present information clearly, correct communication barriers, and involve the patient to the greatest extent possible. When decision-making capacity is lacking, identify an appropriate surrogate through the applicable process while continuing to respect the person's preferences and participation.
Apply it
A patient with mild memory impairment explains a proposed medicine's purpose, major risks, and alternatives and describes a consistent choice. Evaluate that demonstrated understanding rather than automatically seeking permission from an accompanying adult child.
Common pitfall: A cognitive diagnosis does not automatically remove decision-making capacity. Agreement with the clinician is also not the test; a patient may understand the decision and reasonably decline.
12.When do advance directives guide treatment decisions?
Advance directives communicate treatment preferences or identify a decision-maker for circumstances in which the patient cannot decide. They support planning but do not override the current wishes of a patient who has decision-making capacity. Clarify the document's applicability, discuss current goals, and make relevant information available across settings. Ethical principles are broadly useful, but the legal form, activation, and authority of documents depend on the jurisdiction and the specific instrument.
Apply it
A capable patient requests treatment that differs from an older written directive. Discuss the current choice, confirm understanding, and document the updated preference rather than treating the previous document as permanently controlling.
Common pitfall: Treating every advance document as an immediate refusal of treatment ignores its purpose and applicability. Current capable preferences remain central, even when family members prefer the older plan.
13.Why should treatment decisions avoid age-based assumptions?
Chronological age alone does not establish functional ability, expected treatment benefit, capacity, or acceptable burden. Older adults vary widely in health, cognition, resources, and priorities. Individualized treatment frameworks therefore use these characteristics to guide decisions. Avoid assuming either that all older adults need less treatment or that standard intensive treatment suits everyone. Ask what outcome matters and assess whether the proposed intervention can achieve it with a burden the person accepts.
Apply it
Two patients of the same age have different functional abilities and preferences about treatment burden. Assess each person's likely benefit, risks, and ability to carry out the plan rather than withholding useful care solely because of age.
Common pitfall: Age-based therapeutic nihilism can deny useful care. The opposite error is pursuing an intensive target despite frailty, recurrent harm, and a patient's preference for simpler treatment.
ADA: Older Adults — Standards of Care in Diabetes—2026 · AMA Code of Medical Ethics: Informed Consent
14.How can caregivers be partners without displacing the patient?
Caregivers may provide crucial information about function, medication administration, and changes from baseline. Their role should reflect the patient's preferences, decision-making ability, and actual assistance needs. Ask what tasks the caregiver performs, whether training is adequate, and whether the workload is sustainable. Include caregivers in education with appropriate patient involvement and permission. Partnership improves feasibility when it supports the patient's goals rather than automatically transferring control to the most vocal family member.
Apply it
A patient wants a daughter involved in organizing medicines but wishes to make treatment decisions personally. Teach both the administration plan, clarify responsibilities, and assess whether the daughter can sustain the requested assistance.
Common pitfall: Assuming an available relative has unlimited time or authority can undermine both care and autonomy. A caregiver's presence does not establish willingness or competence for every task.
HIGN: Family Caregiving · AMA Code of Medical Ethics: Informed Consent
15.How is the Modified Caregiver Strain Index interpreted?
The Modified Caregiver Strain Index assesses strain across 13 items. Responses score two points for yes, one for sometimes, and zero for no, giving a possible total of 0–26. Higher scores indicate greater strain and warrant closer assessment of needs. The instrument does not establish validated low, moderate, or high categories. Use individual responses to identify practical concerns such as disrupted sleep, financial pressure, or physical demands and plan suitable support.
Apply it
A caregiver scores 17 and reports frequent sleep disruption and work adjustments. Interpret the score as evidence of substantial reported strain requiring further assessment, then explore respite and task-sharing without assigning an unsupported severity category.
Common pitfall: Inventing categorical cutoffs makes the score appear more definitive than the instrument supports. A low total also should not erase a serious concern identified in one response.
HIGN: The Modified Caregiver Strain Index · HIGN: The Modified Caregiver Strain Index Assessment
16.What distinguishes social isolation from loneliness?
Social isolation describes an objective lack of sufficient relationships or interactions, whereas loneliness is the subjective distress associated with a gap between desired and actual connection. A person can live alone without loneliness or feel lonely despite frequent contact. Ask about both the structure and experience of relationships. Match support to the identified problem, such as transportation, accessible community activities, or opportunities for meaningful contact, rather than assuming that contact frequency captures emotional need.
Apply it
A patient living with relatives reports feeling disconnected, while another living alone describes satisfying friendships. Assess each person's desired relationships and barriers before recommending the same group activity or judging need from household size.
Common pitfall: Using living alone as a diagnosis of loneliness confuses circumstance with experience. Simply increasing the number of contacts may not address a lack of meaningful connection.
17.How should support needs influence a home medication plan?
A home plan is feasible only if the required tasks match the patient's abilities and the support actually available. Assess transportation, shopping, meal preparation, medication management, and caregiver capacity together. An apparent adherence problem may reflect inability to obtain medicines or complete essential daily tasks. Identify the specific barrier and connect assistance to it, then confirm that the arrangement operates reliably. A referral alone does not establish that the need has been met.
Apply it
A patient understands the regimen but misses refills because transport has stopped and the caregiver works during pharmacy hours. Arrange a workable supply solution and confirm receipt rather than repeating instructions about the importance of adherence.
Common pitfall: Calling practical barriers unwillingness can lead to ineffective counseling. Assuming a family member will fill every gap can conceal unmet needs and increase caregiver strain.
Therapeutics and Patient Management50%
18.Which kidney function estimate should inform a drug decision?
Kidney-related prescribing requires attention to the medicine's labeling, the units used, and the reliability of the estimate in the individual patient. A reported eGFR and a creatinine-clearance estimate are not interchangeable labels for the same calculation. NIDDK advises using appropriate contemporary estimates and considering more accurate assessment when dosing decisions lie near a cutoff. Identify the relevant threshold and method before deciding whether a dose, interval, or medicine choice is suitable.
Apply it
A medicine's labeling uses a creatinine-clearance threshold, but the chart displays only an indexed eGFR. Review the labeling and obtain an appropriate assessment rather than copying the displayed value into a different dosing framework without interpretation.
Common pitfall: Selecting whichever equation permits the preferred prescription is unsound. The estimate's method, units, patient characteristics, and clinical consequences must be considered together rather than selectively.
NIDDK: Determining Drug Dosing in Adults with Chronic Kidney Disease
19.How is indexed eGFR converted to an absolute filtration estimate?
Laboratories commonly report eGFR normalized to a body surface area of 1.73 m². When an absolute estimate is appropriate for a drug decision, multiply indexed eGFR by the patient's body surface area and divide by 1.73. The resulting units are mL/min rather than mL/min/1.73 m². This adjustment can matter at markedly different body sizes, but it does not convert eGFR into Cockcroft–Gault creatinine clearance or resolve an unreliable filtration estimate.
Apply it
A patient has eGFR 52 mL/min/1.73 m² and body surface area 1.30 m². The absolute estimate is 52 × 1.30 ÷ 1.73, approximately 39 mL/min, which may change interpretation near a labeling threshold.
Common pitfall: Multiplying by 1.73 divided by body surface area reverses the adjustment. Removing indexing also does not justify substituting eGFR for every label-specific renal assessment.
NIDDK: Determining Drug Dosing in Adults with Chronic Kidney Disease
20.When does cystatin C add value to medication assessment?
A combined creatinine–cystatin C estimate can be useful when creatinine-based eGFR may be inaccurate or when greater accuracy could change a consequential treatment decision. Examples include unusual muscle mass and a result near a renal dosing cutoff. The purpose is to reduce uncertainty in filtration assessment, not to select the most permissive result. Interpret the estimate with the overall clinical state and consider measured assessment when uncertainty remains especially important for safety.
Apply it
An older adult with marked muscle wasting has a creatinine-based estimate just above a medicine's renal cutoff. Request a combined creatinine–cystatin C estimate before treating that borderline value as sufficiently reliable for the planned exposure.
Common pitfall: Ordering another marker without specifying the decision it should inform adds little. A confirmatory result should resolve a clinical uncertainty, not merely decorate the chart.
NIDDK: Determining Drug Dosing in Adults with Chronic Kidney Disease
21.Which medicines count toward the Beers CNS-active combination criterion?
The criterion concerns concurrent use of at least three qualifying medicines, including multiple medicines within one category. Included categories are antiepileptics, including gabapentinoids; antidepressants in the TCA, SSRI, or SNRI groups; antipsychotics; benzodiazepines; nonbenzodiazepine benzodiazepine receptor agonist hypnotics, or Z-drugs; opioids; and skeletal muscle relaxants. These combinations increase falls and fracture risk. Count individual medicines, assess each indication, and minimize concurrent exposure through a clinically appropriate plan.
Apply it
Two qualifying antidepressants plus a benzodiazepine total three qualifying medicines even though they represent only two broad categories. The combination meets the criterion and warrants review.
Common pitfall: Counting distinct categories instead of individual medicines misses qualifying combinations. An indication for every medicine does not establish that their cumulative effects are acceptable.
22.How should time to benefit influence treatment planning?
Some treatments prevent events over a prolonged period, while adverse effects and administration burdens may begin immediately. Compare the expected time to meaningful benefit with health status, prognosis, preferences, and the patient's priorities. Distinguish treatments offering near-term symptom relief from those requiring a longer horizon. A limited opportunity to realize preventive benefit can change priorities, but advanced age alone does not establish that benefit is impossible.
Apply it
A patient with advanced illness prioritizes comfortable movement and alert family interaction. Review treatments with delayed preventive aims separately from medicines providing current symptom relief, considering the burdens and benefits of each.
Common pitfall: Assuming every preventive medicine should continue indefinitely ignores changing goals. Assuming every such medicine should stop because someone is old substitutes age for individualized benefit assessment.
ADA: Older Adults — Standards of Care in Diabetes—2026 · NCI: Cancer Pain PDQ — Health Professional Version
23.How does shared decision-making change a medication recommendation?
Shared decision-making combines clinical evidence with the patient's goals, preferences, and acceptable burdens. Explain the purpose, expected benefits, important harms, alternatives, and the option of declining treatment in understandable terms. Then determine which tradeoffs matter most to the patient and agree on a feasible plan. A technically effective regimen may be unsuitable if it conflicts with a central priority or cannot be carried out. Document both the decision and its rationale.
Apply it
Two reasonable regimens differ in injection burden and hypoglycemia risk. After discussing both, a patient prioritizes avoiding lows and maintaining independence. Use those preferences to select and monitor a feasible option rather than maximizing a laboratory target alone.
Common pitfall: Presenting a preferred prescription and requesting agreement is not a full discussion of alternatives. Shared decisions also require accurate information rather than shifting clinical responsibility onto the patient.
AMA Code of Medical Ethics: Informed Consent · ADA: Older Adults — Standards of Care in Diabetes—2026
24.Which glycemic goals fit different older-adult health states?
The ADA framework suggests A1C goals around less than 7.0–7.5% for healthy older adults with intact function and cognition, and less than 8.0% for many with complex or intermediate health. For very complex or poor health, avoid reliance on A1C and focus on avoiding hypoglycemia and symptomatic hyperglycemia. These are individualized frameworks, not automatic assignments. Treatment burden, preferences, functional ability, and the safety of achieving a target remain central.
Apply it
A patient with multiple illnesses and impaired self-management has A1C 6.5% with recurrent lows. Consider a less stringent goal and safer treatment rather than interpreting the result as better control that should be preserved at any cost.
Common pitfall: Assigning a target from age alone ignores the framework's functional and health distinctions. A less stringent target does not mean accepting dehydration or symptomatic hyperglycemia.
25.How can CYP2D6 phenotype change the choice of codeine?
Codeine requires CYP2D6 conversion to morphine for much of its analgesic effect. Poor metabolizers form substantially less morphine and may obtain inadequate relief; ultrarapid metabolizers form more morphine and risk serious toxicity. CPIC recommends avoiding codeine in both phenotypes, for different reasons. Choose an appropriate alternative that does not depend on CYP2D6 activation; tramadol is not a suitable workaround for this mechanism. The primary [CPIC opioid guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC8249478/) provides the phenotype-specific recommendations.
Apply it
A documented CYP2D6 poor metabolizer reports little benefit from codeine despite verified use. Select an appropriate alternative rather than assuming that escalating codeine will overcome inadequate activation.
Common pitfall: Poor metabolism of a prodrug can reduce benefit rather than increase active-drug exposure. Neither age nor ancestry alone establishes an individual's metabolizer phenotype.
BCGP Examination Specifications — Effective January 2024 · NCI: Cancer Pain PDQ — Health Professional Version
26.How is a reliable medication history assembled?
A reliable history combines patient or caregiver interview with appropriate corroborating sources, such as containers, dispensing information, and previous records. Include prescriptions, nonprescription medicines, supplements, and how products are actually taken. Distinguish an ordered regimen from real use, and clarify uncertain names, strengths, schedules, and recent changes. The goal is an accurate baseline for reconciliation; copying a previous list without verification can perpetuate omissions, duplications, and discontinued treatments.
Apply it
An admission list shows a nightly sedative, but the patient says it was stopped and brings a different sleep product. Verify both histories and actual use before continuing either product automatically in the hospital.
Common pitfall: A dispensing record establishes that a product was supplied, not that it is currently taken. Patient recall alone can also miss products or recent changes.
AHRQ MATCH Chapter 3: Designing the Medication Reconciliation Process
27.How are medication discrepancies distinguished from intended changes?
Reconciliation compares an accurate medication history with current orders and clarifies differences. A discrepancy may represent an intentional, clinically justified change or an unintentional omission, duplication, or mismatch. Determine the reason, communicate with the responsible clinician, resolve unintended differences, and document the final plan. Merely displaying two lists is insufficient. The key decision is whether each difference has an understood and appropriate explanation that the next clinician and patient can follow.
Apply it
A discharge regimen omits a long-term medicine without an explanation. Confirm whether it was deliberately stopped, resolve any unintended omission, and ensure the final instructions communicate the decision rather than silently restoring the old prescription.
Common pitfall: Automatically restarting every home medicine can reverse an intentional safety change. Accepting every difference as deliberate can leave genuine omissions or duplications unresolved during a transition.
AHRQ MATCH Chapter 3: Designing the Medication Reconciliation Process
28.What identifies a possible prescribing cascade?
A prescribing cascade occurs when an adverse effect is interpreted as a new condition and another medicine is added to treat it. Suspect the pattern when a symptom begins after a medication start or increase and fits that medicine's effects. Review indication, timing, competing causes, and alternatives before adding treatment. For example, constipation after increased anticholinergic exposure should prompt reassessment of the causal regimen, although symptom relief may still be needed.
Apply it
A patient develops constipation after adding a strongly anticholinergic sleep product. Before recommending a permanent additional medicine, assess the sleep product's necessity and alternatives while addressing the current bowel symptoms and checking for concerning features.
Common pitfall: Temporal association alone does not prove causation. Conversely, treating the new symptom indefinitely without reviewing a plausible medication cause can increase burden and obscure preventable harm.
American Geriatrics Society 2023 Updated AGS Beers Criteria · AGS: Updated Beers Criteria Will Help Ensure Medications Are Appropriate
29.How should deprescribing be planned and monitored?
Deprescribing is a supervised process of reducing or stopping medicines when current harms or burdens outweigh benefits or the indication no longer fits the patient's goals. Review each medicine's purpose, benefit, adverse effects, and withdrawal or rebound risks. Agree on what to change, whether tapering is needed, what symptoms to monitor, and when to review. The objective is an appropriate regimen, not an arbitrary low medicine count or withdrawal of useful treatment.
Apply it
A patient wants fewer medicines and reports daytime sedation. Identify the likely contributor, confirm its indication and dependence risk, agree on a safe reduction plan, and define follow-up for both symptom recurrence and improvement in alertness.
Common pitfall: Stopping several medicines abruptly can create withdrawal and make outcomes difficult to interpret. Medicine count alone cannot distinguish harmful polypharmacy from a justified multidrug regimen.
AGS: Updated Beers Criteria Will Help Ensure Medications Are Appropriate · ASAM: Benzodiazepine Tapering
30.Why should long-term benzodiazepines usually be tapered gradually?
Regular benzodiazepine exposure can produce physical dependence, so abrupt discontinuation can cause serious withdrawal, including seizures. The joint guideline recommends an individualized taper when risks outweigh benefits. An initial pace commonly involves reductions of 5–10% every two to four weeks, generally not exceeding 25% every two weeks, with adjustment to response. These are starting principles rather than a universal schedule; duration of use, symptoms, comorbidity, and patient preference influence the plan.
Apply it
An older adult taking a benzodiazepine daily for years develops falls and wants to stop. Explain dependence and withdrawal risk, then develop a supervised gradual taper with symptom monitoring rather than instructing immediate discontinuation.
Common pitfall: Physical dependence does not by itself establish a substance use disorder. A rigid reduction schedule can also be unsafe when withdrawal symptoms require a slower pace.
ASAM: Benzodiazepine Tapering · Joint Clinical Practice Guideline on Benzodiazepine Tapering
31.How should symptoms change the pace of a benzodiazepine taper?
A taper should respond to the patient's experience rather than proceed automatically through predetermined reductions. Evaluate new anxiety, insomnia, tremor, or other symptoms for withdrawal, recurrence of the original condition, and alternative causes. Significant symptoms may require pausing or slowing the taper and reassessing supports. Continue to weigh the risks of ongoing exposure against withdrawal and functional disruption. A slower taper can preserve engagement and safety without abandoning the agreed long-term objective.
Apply it
After a dose reduction, a patient develops marked insomnia and tremor that disrupt daily activities. Reassess the symptoms and consider holding or slowing further reductions while improving support instead of insisting on the next scheduled decrease.
Common pitfall: Every symptom during a taper is not necessarily withdrawal. Equally, interpreting withdrawal symptoms as proof that lifelong treatment is required can prevent a safer individualized approach.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
32.Which behavioral support strengthens benzodiazepine deprescribing?
Behavioral interventions matched to the underlying problem can support benzodiazepine tapering. The joint guideline recommends offering interventions such as cognitive behavioral therapy or cognitive behavioral therapy for insomnia, alongside treatment of relevant psychiatric or physical conditions. Support should address the reason the medicine was used and practical barriers to reduction. Simply removing the medicine without an alternative management plan can leave symptoms untreated and make an otherwise appropriate taper difficult to sustain.
Apply it
A patient using a benzodiazepine for chronic insomnia agrees to taper but fears sleepless nights. Arrange access to insomnia-focused cognitive behavioral treatment and a follow-up plan while discussing a gradual, symptom-responsive reduction.
Common pitfall: Substituting another sedating medicine automatically can preserve adverse effects without addressing insomnia mechanisms. Behavioral treatment supports a taper but does not eliminate the need to monitor withdrawal.
ASAM: Benzodiazepine Tapering · Joint Clinical Practice Guideline on Benzodiazepine Tapering
33.How should an alendronate tablet be taken?
Take FOSAMAX tablets on arising with a full glass of plain water, 6–8 ounces, at least 30 minutes before the first food, other beverage, or other medicine of the day. Swallow the tablet whole; do not chew or suck it because this can cause oropharyngeal ulceration. Remain upright, sitting or standing, for at least 30 minutes and until after the first food of the day. The fasting instructions support absorption, while the water and upright positioning reduce esophageal irritation. Assess whether the patient can carry out this complete sequence before recommending oral tablet treatment.
Apply it
A patient takes alendronate with coffee and morning tablets, then returns to bed. Teach the patient to take it on arising, swallow it whole without chewing or sucking, and use 6–8 ounces of plain water. Have the patient explain the wait of at least 30 minutes before food, other beverages, or medicines and the need to remain upright for at least 30 minutes and until after the first food.
Common pitfall: Remembering only the fasting interval misses safeguards against local injury. Chewing or sucking can cause oropharyngeal ulceration, and returning to bed violates the upright requirement. Coffee, mineral water, other beverages, food, and concurrent medicines do not substitute for the specified plain-water administration.
34.When is an oral alendronate tablet unsuitable, and which symptoms require stopping it?
FOSAMAX labeling contraindicates tablets in abnormalities of the esophagus that delay emptying, such as stricture or achalasia, and in patients unable to stand or sit upright for at least 30 minutes. Hypocalcemia is also a contraindication. Assess swallowing and positioning capability and review alternative treatment approaches when a contraindication exists. Teach patients to discontinue FOSAMAX and seek medical attention if they develop dysphagia, painful swallowing, retrosternal pain, or new or worsening heartburn.
Apply it
A patient with a documented esophageal stricture is prescribed an alendronate tablet. Identify the contraindication and contact the prescriber to reconsider treatment. If a patient already taking FOSAMAX develops painful swallowing or new heartburn, instruct the patient to discontinue it and seek medical attention.
Common pitfall: Careful technique cannot remove an esophageal contraindication. New esophageal symptoms require discontinuation and medical attention, rather than continued dosing with extra water or treatment of heartburn alone.
35.How should calcium be separated from levothyroxine?
Calcium products can reduce levothyroxine absorption and make a previously effective regimen appear inadequate. SYNTHROID labeling directs separation by at least four hours from medicines known to interfere with absorption, including calcium supplements. Review actual timing and consistency before concluding that a dose is insufficient. Correcting an interaction changes exposure, so arrange appropriate reassessment rather than increasing treatment automatically and later creating over-replacement when the administration problem is corrected.
Apply it
A patient's thyroid test changes after calcium is added to the same breakfast-time medicine routine. Clarify actual administration, separate calcium from levothyroxine by at least four hours, and plan reassessment before assuming the thyroid condition has progressed.
Common pitfall: Increasing levothyroxine without reviewing administration can compensate for an avoidable interaction. Once calcium timing changes, that higher dose may produce excessive thyroid hormone exposure.
36.Why do potassium salt substitutes matter with spironolactone?
Spironolactone reduces potassium excretion and can cause hyperkalemia, especially with impaired kidney function or other potassium-raising exposures. Potassium-containing salt substitutes may supply a substantial additional potassium load despite being perceived as a healthy dietary choice. Ask specifically about these products, potassium supplements, and interacting medicines. Assess the indication and laboratory results, remove avoidable contributors when appropriate, and ensure follow-up. The relevant mechanism is potassium accumulation, not sodium content alone.
Apply it
A patient taking spironolactone switches to a potassium-based salt substitute and later has an elevated potassium result. Review the product and other potassium-raising exposures promptly rather than focusing only on whether dietary sodium has decreased.
Common pitfall: A product marketed as a salt alternative is not automatically safe with potassium-sparing treatment. Normal earlier potassium does not guarantee safety after a new potassium exposure.
37.When should bacteriuria in an older adult remain untreated?
Asymptomatic bacteriuria is bacterial growth in urine without symptoms attributable to urinary infection. IDSA recommends against screening or treating many older adult populations, including long-term care residents, solely for this finding. In a stable older adult with delirium or a fall but no local urinary symptoms or systemic infection signs, assess other causes and observe rather than automatically prescribe antibiotics. Treatment decisions should follow the clinical syndrome, because a positive culture alone does not establish symptomatic infection.
Apply it
A stable resident has a positive urine culture obtained after a fall but no dysuria, urinary urgency, fever, or hemodynamic instability. Evaluate the fall and other contributors instead of using the culture alone to justify antibiotics.
Common pitfall: Pyuria or a positive culture does not prove symptomatic urinary infection. This principle does not justify withholding urgent evaluation or treatment from a patient with systemic instability.
IDSA Clinical Practice Guideline for Asymptomatic Bacteriuria
38.Which urologic procedures create an exception for asymptomatic bacteriuria?
IDSA recommends screening for and treating asymptomatic bacteriuria before endoscopic urologic procedures associated with mucosal trauma because bacteriuria increases the risk of postoperative sepsis. Obtain a culture and use targeted rather than purely empirical treatment when possible. The exception is tied to the type of procedure, not simply the patient's age, residence, or positive culture. Distinguish a planned mucosa-traumatizing intervention from procedures that do not carry the same infectious risk.
Apply it
An asymptomatic patient with bacteriuria is scheduled for an endoscopic urologic procedure expected to traumatize mucosa. Confirm the culture-directed peri-procedural plan instead of applying the usual older-adult nontreatment rule without considering the procedure.
Common pitfall: Generalizing this exception to every procedure or every positive culture promotes unnecessary antibiotics. The discriminating feature is the planned urologic intervention's associated mucosal trauma.
IDSA Clinical Practice Guideline for Asymptomatic Bacteriuria
39.How should a monitoring plan measure benefit and burden together?
Specify the desired clinical outcome, relevant adverse effects, patient-reported burden, and reassessment timing. In cancer pain care, assess pain relief alongside alertness, bowel function, activity, and rescue use. Define what would trigger adjustment: persistent sedation can make improved pain intensity unacceptable, while frequent rescue use can indicate inadequate baseline control. Monitoring should establish whether treatment improves the activities the patient values with tolerable adverse effects.
Apply it
After an analgesic change, pain intensity falls but the patient cannot stay awake for visits. Review the treatment and other contributors to sedation against the agreed goal of alert interaction.
Common pitfall: A numerical improvement can conceal worsening function. Collecting measurements without specifying how concerning findings will change the plan leaves important harms unresolved.
40.When should potassium be checked after spironolactone changes?
Spironolactone labeling calls for potassium monitoring within one week of initiation or titration and regularly thereafter. More frequent monitoring may be needed with impaired kidney function or other potassium-raising drugs. Assess renal function and relevant coexposures alongside potassium rather than treating the result in isolation. A previously stable regimen can become riskier after a dose change, declining kidney function, or a new interacting product, so monitoring must follow changes in risk.
Apply it
Spironolactone is increased in a patient with reduced kidney function who also uses a renin–angiotensin system medicine. Arrange potassium assessment within one week and determine whether closer follow-up is needed based on the combined risk.
Common pitfall: A normal baseline potassium is not a substitute for post-change monitoring. Waiting for symptoms can miss clinically important hyperkalemia before a patient recognizes a problem.
41.Why is thyroid hormone over-replacement especially consequential?
Excess levothyroxine can produce hyperthyroid effects, including cardiac adverse reactions and increased bone resorption with reduced bone mineral density. Older adults and people with cardiovascular disease require particular attention to excessive exposure. Review symptoms, thyroid tests, dose history, adherence, and interactions before adjusting treatment. A new administration pattern that improves absorption can expose an excessive dose previously masked by interference. The aim is appropriate replacement, not a maximally suppressed thyroid-stimulating hormone in routine hypothyroidism treatment.
Apply it
A patient develops palpitations after separating levothyroxine from calcium while continuing a recently increased dose. Review thyroid testing and the exposure change rather than assuming the palpitations are unrelated to a medicine taken for many years.
Common pitfall: Longstanding use does not rule out current over-replacement. Treating a suppressed thyroid-stimulating hormone as desirable without considering the indication can expose patients to avoidable harm.
42.When should hypoglycemia-causing treatment be deintensified?
The ADA recommends deintensifying hypoglycemia-causing medicines or switching to lower-risk approaches when an older adult has high hypoglycemia risk, within individualized goals. Recurrent lows, inability to execute the regimen, cognitive decline, or burdens exceeding likely benefit are important cues. A1C summarizes average exposure and can conceal alternating highs and lows; review their timing rather than relying on the average alone. Simplification should reduce unsafe administration decisions while preserving protection from symptomatic hyperglycemia.
Apply it
A patient has repeated low glucose despite an A1C above the preferred target and struggles with a complex insulin schedule. Review the cause and timing of lows and simplify the plan rather than intensifying solely to lower the average.
Common pitfall: An elevated A1C does not exclude overtreatment during parts of the day. Deintensification should preserve protection from symptomatic hyperglycemia rather than remove monitoring and follow-up.
43.How should an apparent adherence problem be investigated?
Determine whether the patient understands the regimen, can perform its tasks, can obtain the products, and accepts the treatment. These are different barriers requiring different responses. Functional assessment can identify difficulty with medication management, while reconciliation clarifies actual use versus recorded orders. Ask nonjudgmentally about missed doses and observe relevant tasks when possible. An effective intervention addresses the demonstrated cause and is checked afterward, rather than assuming that another explanation of the prescription will solve the problem.
Apply it
A patient misses doses despite accurately repeating instructions. Observation reveals difficulty handling the organizer. Adjust the delivery system or assistance and reassess actual use instead of repeatedly providing the same written schedule.
Common pitfall: Labeling all missed doses forgetfulness can obscure dexterity, access, or preference barriers. A dispensing refill history alone cannot establish that doses were administered correctly.
HIGN Lawton IADL Assessment · AHRQ MATCH Chapter 3: Designing the Medication Reconciliation Process
44.Which outcomes matter in cancer pain assessment?
Cancer pain assessment includes intensity, location, quality, temporal pattern, aggravating factors, treatment response, adverse effects, and effects on function and quality of life. The patient's report is central when communication is possible. A numerical score alone cannot determine whether treatment is successful or acceptable. Agree on meaningful goals such as sleeping, moving, or interacting with family, and reassess both analgesia and treatment burden. Changes in the pain pattern can require reassessment of its cause.
Apply it
A patient reports a lower pain score but is too sleepy to converse, which conflicts with the stated goal of family interaction. Reassess analgesic benefit and sedation together rather than declaring success from the score alone.
Common pitfall: Escalating treatment solely to reach a numerical score may undermine patient priorities. Conversely, quiet behavior does not establish absence of pain when communication is limited.
45.What bowel regimen should accompany ongoing opioid treatment for cancer pain?
Opioids decrease peristalsis, and tolerance generally does not resolve the resulting constipation. After assessing baseline bowel function and contraindications, start a scheduled stimulant laxative such as senna when regular opioid treatment begins. Individualize titration and monitor frequency, straining, discomfort, and stool consistency. NCI gives an example goal of one unforced bowel movement every one to two days and states that adding a stool softener offers no further benefit. Persistent constipation or concerning symptoms require assessment, including for obstruction or impaction when indicated.
Apply it
A patient beginning regular morphine has normal bowel function. Start scheduled senna with an individualized titration and monitoring plan rather than using docusate alone or waiting for painful constipation.
Common pitfall: Hydration and activity can support bowel care but do not reliably replace pharmacologic prevention. Severe pain, vomiting, or suspected obstruction requires assessment before routine laxative escalation.
46.How does breakthrough pain differ from inadequately controlled persistent pain?
Breakthrough pain is a transient pain flare occurring against a background of otherwise controlled persistent pain. Pain that remains poorly controlled much of the day suggests that the baseline problem needs reassessment rather than repeated treatment of isolated episodes alone. Examine timing, triggers, duration, relief, and relationship to scheduled treatment. Frequent rescue use is information about the overall plan, not just a reason to keep repeating the same response without reassessing efficacy and adverse effects.
Apply it
A patient describes brief movement-triggered flares but reasonable comfort at rest, while another has pain throughout the dosing interval. Characterize both patterns before recommending the same rescue-focused adjustment for their different pain problems.
Common pitfall: Calling all recurrent pain breakthrough pain can conceal inadequate baseline control. Automatically increasing scheduled treatment for occasional predictable flares can also increase adverse effects between episodes.
47.How should palliative goals guide medication tradeoffs?
Palliative medication decisions should reflect the symptoms and activities the patient values, expected benefit, and acceptable adverse effects. Relief of pain may be central, but sedation, constipation, and treatment complexity also affect quality of life. Clarify whether the priority is sleep, mobility, alert interaction, or another outcome, and reassess after changes. Explicit prescribing criteria require contextual interpretation; the Beers Criteria are not intended for hospice and end-of-life settings, where goals and tradeoffs differ.
Apply it
A patient with advanced cancer accepts some drowsiness overnight but prioritizes alertness for daytime visits. Use that preference to guide review of analgesia and adverse effects rather than assuming maximal sedation or complete pain elimination is desired.
Common pitfall: Assuming all palliative patients accept the same tradeoff ignores individual priorities. Applying an explicit medication list without considering its stated setting can also misdirect treatment decisions.
NCI: Cancer Pain PDQ — Health Professional Version · American Geriatrics Society 2023 Updated AGS Beers Criteria
Professional Practice21%
48.How should Beers Criteria findings influence a recommendation?
The AGS Beers Criteria identify potentially inappropriate medicines and important medication–disease, interaction, and kidney-related concerns in older adults. A listed medicine is a signal for review, not an automatic prohibition in every circumstance. Consider indication, alternatives, prior response, goals, and the feasibility of change. Explain the specific risk relevant to the patient and develop a plan through shared decisions. The criteria support clinical judgment and medication review rather than replacing either.
Apply it
A review flags a medicine that has provided substantial benefit after alternatives failed. Assess the relevant risk and possible mitigation with the patient instead of stopping it solely because its name appears on the list.
Common pitfall: Treating a screening criterion as an absolute rule can remove useful treatment. Ignoring a flag without examining the stated risk loses the tool's safety value.
AGS: Updated Beers Criteria Will Help Ensure Medications Are Appropriate · American Geriatrics Society 2023 Updated AGS Beers Criteria
49.What different problems do STOPP and START identify?
STOPP identifies potentially inappropriate prescribing, while START identifies potential prescribing omissions. Together they encourage review of both unnecessary or harmful treatment and missing beneficial treatment. Apply individual criteria to the patient's diagnoses, contraindications, preferences, and goals rather than interpreting a screen as a final prescription. Medication optimization can require stopping, changing, continuing, or adding treatment. An apparently short regimen is not necessarily appropriate if an important indicated therapy has been omitted.
Apply it
A review finds one medicine without a current indication and a separate untreated condition with a potentially beneficial therapy. Use STOPP-oriented reasoning for the first problem and START-oriented reasoning for the second, then assess patient-specific suitability.
Common pitfall: Using both tools only to reduce medicine count misses prescribing omissions. A START signal still requires assessment of contraindications, expected benefit, and the patient's treatment preferences.
STOPP/START Criteria for Potentially Inappropriate Prescribing: Version 3
50.How does aspirin's preventive indication change its appropriateness?
Primary prevention seeks to prevent a first cardiovascular event; secondary prevention addresses established cardiovascular disease. The 2023 Beers Criteria recommend avoiding initiation of aspirin for primary prevention in older adults because bleeding risk increases and net benefit is lacking. Aspirin is generally indicated for secondary prevention. Establish the indication before recommending a change.
Apply it
An older adult without established cardiovascular disease asks to start daily aspirin. Explain the primary-prevention concern rather than extrapolating its secondary-prevention benefit.
Common pitfall: Do not apply this recommendation automatically to aspirin after a cardiovascular event. Review existing primary-prevention use individually.
51.What makes a medication handoff useful across care settings?
A useful handoff communicates the reconciled regimen, important starts and stops, reasons for changes, unresolved questions, and required follow-up. The next clinician and the patient need to know what to do, not merely receive another medicine list. AHRQ's reconciliation framework emphasizes a defined process across transitions. Assign responsibility for resolving discrepancies and monitoring after discharge. Clear communication reduces the chance that an intentionally stopped medicine is restarted or a needed follow-up test is missed.
Apply it
A hospital stops a sedating medicine after falls and changes another treatment requiring follow-up. Include both the stop rationale and the monitoring responsibility in the discharge communication so the receiving team can maintain the intended plan.
Common pitfall: A complete-looking list can conceal why changes occurred and who must act next. Sending several conflicting lists transfers uncertainty rather than completing medication reconciliation.
AHRQ MATCH Toolkit for Medication Reconciliation · AHRQ MATCH Chapter 3: Designing the Medication Reconciliation Process
52.Why should a reconciliation improvement be pilot-tested?
A proposed reconciliation process may fail because responsibilities, timing, communication, or documentation do not fit the actual workflow. AHRQ recommends developing and pilot-testing changes before wider implementation. Start with a manageable setting, observe how the process operates, gather feedback, and revise it using defined measures. A pilot should test whether discrepancies are identified and resolved reliably, not merely whether staff can complete a new form. Expand when practical problems have been addressed.
Apply it
A pharmacy team proposes a new admission-history process. Trial it on one unit, review unresolved discrepancies and staff handoffs, and revise unclear responsibilities before introducing the same workflow throughout the organization.
Common pitfall: Organization-wide rollout before testing can spread avoidable process failures. A successful demonstration by the project team does not prove reliability during ordinary shifts and competing clinical demands.
53.How should reconciliation quality be measured?
Use defined process and safety measures that show whether reconciliation occurs accurately and whether discrepancies are resolved. Completion rates can describe workflow reliability, while review of unintended discrepancies and related harm assesses the safety purpose. Define the eligible population, numerator, denominator, timing, and data source before comparing results. AHRQ emphasizes assessment and process evaluation. A checked box alone does not establish an accurate history, appropriate resolution, or effective communication to the patient and next team.
Apply it
A service reports 98% completion but chart review finds unresolved dose mismatches. Retain the completion measure while adding a defined discrepancy-resolution assessment, then use both findings to identify where the process is failing.
Common pitfall: Confusing documentation completion with clinical accuracy rewards superficial compliance. Comparing percentages without consistent definitions can also create an apparent improvement that reflects measurement changes rather than safer care.
54.Why can avoiding routine urine cultures improve population care?
In populations for whom asymptomatic bacteriuria screening is not recommended, unnecessary cultures create opportunities to treat colonization rather than infection. Antibiotics then expose patients to adverse effects and promote resistance without the expected benefit of treating symptomatic disease. A quality strategy should define appropriate testing indications and monitor both prescribing and clinical safety. Preserve the recognized exceptions and prompt evaluation of systemic illness; reducing low-value testing should not become a barrier to necessary assessment.
Apply it
A long-term care facility routinely cultures urine during otherwise asymptomatic annual reviews. Replace that practice with symptom-informed testing guidance, educate staff about bacteriuria, and monitor unnecessary antibiotic treatment alongside safety outcomes.
Common pitfall: Reducing antibiotics without addressing unnecessary testing leaves a major driver intact. A blanket prohibition on urine testing would also ignore symptomatic patients and relevant procedural exceptions.
IDSA Clinical Practice Guideline for Asymptomatic Bacteriuria
55.Which information makes a medication safety alert actionable?
An actionable alert connects a specific risk to relevant patient information and a clear next step. For spironolactone, that can include a recent dose increase, potassium-raising coexposures, and whether the required potassium test has occurred. The BCGP outline includes clinical decision support within informatics; the drug label establishes the monitoring content. Design review should assess whether the alert helps resolve the risk and whether follow-up responsibility is clear, rather than counting alerts displayed.
Apply it
A system flags spironolactone after titration but shows neither laboratory timing nor an action. Improve the message to display the change and monitoring status and direct the responsible clinician to arrange the indicated potassium assessment.
Common pitfall: A generic warning may be acknowledged without correcting the problem. The existence of electronic decision support does not prove that monitoring occurred or that responsibility was assigned.
BCGP Examination Specifications — Effective January 2024 · DailyMed: Spironolactone Prescribing Information
56.How do absolute and relative risk reductions differ?
Absolute risk reduction is control risk minus treatment risk; relative risk reduction divides that difference by control risk. If an event decreases from 12% to 9%, the absolute reduction is three percentage points and the relative reduction is 25%. Both describe the same comparison, but absolute benefit depends on baseline risk. State the outcome, population, and follow-up period when communicating results. A large relative reduction can correspond to a small absolute benefit when baseline risk is low.
Apply it
A trial reports events in 8% of controls and 6% of treated participants over two years. Calculate an absolute reduction of two percentage points and a relative reduction of 25%, then explain both with the timeframe.
Common pitfall: Reporting a two-percentage-point reduction as a 2% relative reduction confuses scales. Relative benefits should not be transferred to a patient without considering baseline risk and applicability.
Cochrane Handbook Chapter 6: Effect Measures · Cochrane Handbook Chapter 15: Interpreting Results
57.How is number needed to treat calculated and interpreted?
Number needed to treat is the reciprocal of an absolute risk reduction expressed as a proportion. An absolute reduction of 0.04 gives an NNT of 25. Interpret it as the number treated, over the specified follow-up, for one additional person to avoid the defined event on average compared with the comparator. Round a noninteger result upward for the conventional whole-person expression. NNT depends on baseline risk, outcome, comparator, and duration; it is not a universal property of a medicine.
Apply it
Over three years, an event occurs in 14% of controls and 10% of treated participants. The absolute reduction is 0.04, giving NNT 25 over three years for the event measured in that study.
Common pitfall: Using four rather than 0.04 in the reciprocal creates a major arithmetic error. Omitting the outcome and follow-up makes an otherwise correct NNT clinically incomplete.
58.What does a confidence interval reveal about a treatment estimate?
A confidence interval conveys uncertainty and precision around an estimated effect. For a risk ratio, the no-effect value is one; for a risk difference, it is zero. An interval spanning the relevant null value does not establish equivalence or prove no effect. Examine whether the interval includes clinically meaningful benefit and harm, and consider study quality and applicability. A narrow interval around a trivial effect may be less clinically useful than statistical significance initially suggests.
Apply it
A trial reports a risk ratio of 0.90 with a 95% confidence interval of 0.65–1.25. Explain that the estimate remains compatible with meaningful benefit and harm rather than declaring the treatments equivalent.
Common pitfall: Treating a nonsignificant result as proof of no difference confuses uncertainty with equivalence. Statistical significance also does not by itself establish a clinically important effect.
Cochrane Handbook Chapter 6: Effect Measures · Cochrane Handbook Chapter 15: Interpreting Results
59.When does one treatment economically dominate another?
A treatment dominates a comparator when it is less costly and more effective under the stated analysis. A more costly, less effective treatment is dominated. When an option costs more and works better, a tradeoff exists and an incremental cost-effectiveness analysis may be useful; the sign of a ratio alone is insufficient. Specify perspective, included costs, outcomes, and time horizon. Dominance is conditional on the estimates and assumptions, so uncertainty and relevant omitted costs still matter.
Apply it
From a clinic perspective over one year, program A costs 900 units and prevents eight events per 100 patients; program B costs 1,100 units and prevents six. A dominates B on the stated costs and outcome.
Common pitfall: A negative incremental ratio can represent dominance or inferiority depending on the signs of both differences. Lower acquisition cost alone does not establish lower total cost.
Cochrane Handbook Chapter 20: Economic Evidence · ISPOR Book of Terms: Health Care Cost, Quality, and Outcomes
60.What does the AMA informed-consent standard require?
AMA Code opinion 2.1.1 is a physician ethical standard, not a universal pharmacy regulation. It calls for assessing understanding and voluntary choice; explaining the diagnosis, proposed intervention, burdens, risks, benefits, and alternatives, including no treatment; and documenting the conversation and decision. A capable patient may decline after this discussion. Its emergency exception concerns an urgent decision when the patient cannot participate and no surrogate is available; the patient or surrogate should be informed at the earliest opportunity and consent obtained for ongoing care.
Apply it
A capable patient declines a medicine after explaining the tradeoffs. Document the discussion and decision and offer appropriate follow-up. A signed form alone does not demonstrate that understanding and voluntary choice were assessed.
Common pitfall: Do not infer incapacity from refusal or use the emergency exception merely because discussion is inconvenient. Applicable legal requirements and professional scope still depend on jurisdiction.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use onset, fluctuation, attention, and baseline function to distinguish acute cognitive change from chronic impairment.
- Assess actual IADL performance, medication-management ability, caregiver capacity, and barriers to community support.
- Distinguish reduced hepatic clearance from increased CNS sensitivity, and interpret kidney estimates and label-specific thresholds.
- Integrate glycemic patterns, cognition, functional ability, time to benefit, and patient priorities into treatment goals.
- Apply CYP2D6 phenotype to codeine selection, distinguishing inadequate activation from excessive active-metabolite formation.
- Recognize cumulative anticholinergic burden and count individual qualifying medicines for the Beers CNS-active combination criterion.
- Practise complete administration counseling and monitoring for alendronate, levothyroxine, and spironolactone.
- Distinguish asymptomatic bacteriuria from symptomatic illness and recognize the mucosa-traumatizing urologic procedure exception.
- Start concrete opioid bowel prevention and monitor analgesia, alertness, bowel function, and patient-valued activities.
- Distinguish aspirin primary from secondary prevention and apply informed-consent standards within their stated professional scope.
- Use reconciliation, appropriateness tools, outcome measures, and clear handoffs to improve continuity and medication safety.
- Calculate absolute effects, relative effects, NNT, and economic dominance while retaining outcome, timeframe, perspective, and uncertainty.
- Map remaining study needs to every topic in the full BPS outline; these selected concepts do not exhaust specialty pharmacotherapy or professional practice.
A practical preparation plan
1. Map the official scope
Create a study map using the three official domains and their subdomains. Allocate roughly half of study time to Therapeutics and Patient Management, then divide the remainder approximately 29:21 between patient population and professional practice.
2. Build a geriatric assessment routine
For each case, establish the cognitive baseline, functional abilities, goals, support system, actual medication use, and recent changes. State which finding changes the decision rather than merely listing risk factors.
3. Work through treatment decisions
Practise choosing a goal, checking renal, hepatic, pharmacogenomic, and administration constraints, resolving discrepancies, identifying cumulative harm, and defining follow-up. Include both stopping inappropriate treatment and recognizing potentially beneficial omissions.
4. Complete the independent question set
Answer all 20 questions before reviewing explanations. For each missed question, explain why the decisive clinical cue supports the correct option and why each alternative fails in that specific case.
5. Rehearse calculations and counseling details
Use flashcards to rehearse eGFR de-indexing, ARR, RRR, NNT, caregiver strain scoring, administration intervals, and monitoring timing. Explain the clinical limitation of each calculation or instruction.
6. Close gaps against the full outline
Revisit additional diseases, pharmacogenomics, preventive care, practice standards, regulations, and informatics using appropriate current references. Confirm the blueprint for the intended administration and use mixed cases to test integration across domains.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- BPS Geriatric Pharmacy
- BPS Examination Content Outlines
- BCGP Examination Specifications — Effective January 2024
- Certified Geriatric Pharmacist Credential Moves to BPS
- BPS Update on Specialties
- NIDDK: Determining Drug Dosing in Adults with Chronic Kidney Disease
- MedlinePlus: Delirium
- HIGN: The Lawton Instrumental Activities of Daily Living Scale
- HIGN Lawton IADL Assessment
- AMA Code of Medical Ethics: Informed Consent
- AMA Code of Medical Ethics: Advance Directives
- HIGN: Family Caregiving
- HIGN: The Modified Caregiver Strain Index
- WHO: Social Connection
- American Geriatrics Society 2023 Updated AGS Beers Criteria
- AGS: Updated Beers Criteria Will Help Ensure Medications Are Appropriate
- ASAM: Benzodiazepine Tapering
- Joint Clinical Practice Guideline on Benzodiazepine Tapering
- ADA: Older Adults — Standards of Care in Diabetes—2026
- IDSA Clinical Practice Guideline for Asymptomatic Bacteriuria
- AHRQ MATCH Toolkit for Medication Reconciliation
- AHRQ MATCH Chapter 3: Designing the Medication Reconciliation Process
- AHRQ MATCH Chapter 4: Developing and Pilot Testing Change
- AHRQ MATCH Chapter 6: Assessment and Process Evaluation
- DailyMed: Spironolactone Prescribing Information
- DailyMed: FOSAMAX Prescribing Information
- DailyMed: SYNTHROID Prescribing Information
- NCI: Cancer Pain PDQ — Health Professional Version
- Cochrane Handbook Chapter 6: Effect Measures
- Cochrane Handbook Chapter 15: Interpreting Results
- STOPP/START Criteria for Potentially Inappropriate Prescribing: Version 3
- Cochrane Handbook Chapter 20: Economic Evidence
- ISPOR Book of Terms: Health Care Cost, Quality, and Outcomes
- HIGN: The Modified Caregiver Strain Index Assessment
- BCGP-Examination-Specifications-2024.pdf
- 2.1.1.pdf
- code-2016-ch5.pdf
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.